date,title,source
Nov-01-18,AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study of MS1819-SD in CF Patients with EPI,GlobeNewswire
Dec-04-18,AZRX: 3Q:18 Financial and Operational Summary,Zacks Small Cap Research
Dec-04-18,AzurRx BioPharma to Present at Upcoming Investor Conferences,GlobeNewswire
Dec-12-18,AzurRx BioPharma to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences Group,GlobeNewswire
Dec-19-18,AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients,GlobeNewswire
Feb-20-19,AzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical Trial,GlobeNewswire
Mar-12-19,AzurRx BioPharma Announces Poster Presentation at the Americas Hepato-Pancreato-Biliary Association 2019 Annual Meeting,GlobeNewswire
Mar-15-19,AzurRx BioPharma to Present at the 2019 Annual Roth Capital Conference (March 19) and the Oppenheimer 29th Annual Healthcare Conference (March 20),GlobeNewswire
Mar-18-19,AzurRx BioPharma Announces Presentation on Its Positive Phase II Data in MS1819-SD in Chronic Pancreatitis at the 2019 Digestive Disease Week Conference,GlobeNewswire
Apr-02-19,Expanded MS1819-SD Global Commercialization Rights Now Owned by AzurRx BioPharma along with Full Development Rights,GlobeNewswire
Apr-11-19,AZRX: CF Study Up and Enrolling; Target to $8,Zacks Small Cap Research
Apr-23-19,AzurRx BioPharma Exceeds 50% Enrollment Target for Phase II OPTION Clinical Trial,GlobeNewswire
May-20-19,AzurRx BioPharma Presents Positive Secondary Endpoint Data in its Phase II MS1819-SD Chronic Pancreatitis Study at the 2019 Digestive Disease Week Conference,GlobeNewswire
May-23-19,AZRX: Secondary Endpoint Data Released for MS1819-SD in Chronic Pancreatitis Patients,Zacks Small Cap Research
May-23-19,AzurRx BioPharma Reaches Enrollment Target for Phase II OPTION Clinical Trial,GlobeNewswire
